"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
(Generic versions may still be available.)
Cinobac (cinoxacin) is indicated for the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K.pneumoniae), and Enterobacter species.
Cinobac (cinoxacin) is effective in preventing urinary tract infections for up to 5 months in women with a history of recurrent urinary tract infections.
In vitro susceptibility testing should be performed prior to administration of the drug and, when clinically indicated, during treatment.
DOSAGE AND ADMINISTRATION
The usual adult dosage for the treatment of urinary tract infections is 1 g daily, administered orally in 2 or 4 divided doses (500 mg b.i.d. or 250 mg q.i.d. respectively) for 7 to 14 days. Doses should be administered at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or Videx (didanosine) chewable tablets or the pediatric powder for oral solution. Although susceptible organisms may be eradicated within a few days after therapy has begun, the full treatment course is recommended.
Impaired Renal Function: When renal function is impaired, a reduced dosage must be employed. After an initial dose of 500 mg, a maintenance dosage schedule should be used (see table).
|MAINTENANCE DOSAGE GUIDE |
FOR PATIENTS WITH RENAL IMPAIRMENT
| Creatinine |
|>80||Normal|| 500 mg |
| 250 mg |
|50-20|| Moderate |
| 250 mg |
|<20|| Marked |
Administration of Cinobac (cinoxacin) to anuric patients is not recommended.
When only serum creatinine is available, the following formula (based on sex, weight and age of patient) may be used to convert this value into creatinine clearance.
The serum creatinine should represent a steady state of renal function.
|Males:|| Weight (kg) x (140 - age) |
72 x serum creatinine
|Females:||0.9 x male value|
Preventive Therapy: A single dose of 250 mg at bedtime for up to 5 months has been shown to be effective in women with a history of recurrent urinary tract infections.
250 mg orange and green, imprinted with "OCL 55" on the cap and "CINOBAC (cinoxacin) 250 mg" on the body, (UC 5355)-(40s) NDC 55515-055-02
500 mg orange and green, imprinted with "OCL 56" on the cap and "CINOBAC (cinoxacin) 500 mg" on the body, (UC 5356)-(50s) NDC 55515-056-04
Storage: Store at controlled room temperature, 59° to 86° F (15° to 30° C).
1. National Committee for Clinical Laboratory Standards, Performance standards for antimicrobial disk susceptibility tests- 5th ed. Appoved Standard NCCLS Document M2-A5, Vol 13, No 24, NCCLS, Villanova, PA 1993.
2. National Committee for Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically- 3rd ed. Approved Standard NCCLS Document M7-A3, Vol 13, No 25, NCCLS, Villanova, PA, 1993.
CAUTION: Federal (USA) law prohibits dispensing without prescription.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Cinobac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.